Press Releases about Annovis Bio IncFrom Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
November 02, 2023
From Annovis Bio
Via Business Wire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From Annovis Bio, Inc.
Via Business Wire
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
January 25, 2022
Via Newsfile
Exposures
Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|